| [1] |
Kim K, Lee E, Lee J, et al. Clinicopathologic signature of TNBC patients with good prognosis[J]. Cancer Res, 2009, 69(24 Suppl):4065.
|
| [2] |
Park Y, Chang M, Lee S, et al. Heterogeneity of triple negative breast cancer (TNBC): TNBC might be divided into two or more subgroups by clinicopathologic findings[J]. Cancer Res, 2010, 69(24 Supplement):6032.
|
| [3] |
Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype[J]. Clin Cancer Res, 2008, 14(5):1368-1376.
|
| [4] |
Chacon RD, Costanzo MV. Triple-negative breast cancer[J]. Breast Cancer Res, 2010, 24(2):S3.
|
| [5] |
Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need[J]. Oncologist, 2011, 16(Suppl 1):1-11.
|
| [6] |
Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options[J]. Chemother Res Pract, 2011:696208.
|
| [7] |
Che HL, Bae IH, Lim KS, et al. Novel fabrication of microRNA nanoparticle-coated coronary stent for prevention of post-angioplasty restenosis[J]. Korean Circ J, 2016, 46(1):23-32.
|
| [8] |
Hayward SL, Francis DM, Kholmatov P, et al. Targeted delivery of microRNA125a-5p by engineered lipid nanoparticles for the treatment of HER2 positive metastatic breast cancer[J]. J Biomed Nanotechnol, 2016, 12(3):554-568.
|
| [9] |
Zhong Y, Zhang J, Cheng R, et al. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts[J]. J Control Release, 2015, 205:144-154.
|
| [10] |
Deng X, Cao M, Zhang J, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer[J]. Biomaterials, 2014, 35(14):4333-4344.
|
| [11] |
Pozzi D, Marchini C, Carfarelli F, et al. Transfection efficiency boost of cholesterol-containing lipoplexes[J]. Biochim Biophys Acta, 2012, 1818(9):2335-2343.
|
| [12] |
Kong F, Zhou F, Ge L, et al. Mannosylated liposomes for targeted gene delivery[J]. Int J Nanomedicine, 2012, 7:1079-1089.
|
| [13] |
Huang Y, Yang T, Zhang W, et al. A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo[J]. Int J Nanomedicine, 2014, 9:4581-4595.
|
| [14] |
Carmona S, Jorgensen MR, Kolli S, et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles[J]. Mol Pharm, 2009, 6(3):706-717.
|
| [15] |
Kenny GD, Kamaly N, Kalber TL, et al. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo[J]. J Control Release, 2010, 149(2):111-116.
|
| [16] |
Sun X, Pang Z, Ye H, et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome[J]. Biomaterials, 2012, 33(3):916-924.
|
| [17] |
Piovan C, Palmieri D, Di Leva G, et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer[J]. Mol Oncol, 2012, 6(4):458-472.
|
| [18] |
Mackiewicz M, Huppi K, Pitt JJ, et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA[J]. Breast cancer Res Treat, 2011, 130(2):663-679.
|
| [19] |
Adams BD, Parsons C, Slack FJ. The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas[J]. Expert Opin Ther Targets, 2016, 20(6):737-753.
|
| [20] |
Pecot CV, Calin GA, Coleman RL, et al. RNA interference in the clinic: challenges and future directions[J]. Nat Rev Cancer, 2010, 11(1):59-67.
|
| [21] |
Lee JS, Anlone M, Pieters E, et al. Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: comparison with stealth liposomes[J]. J Control Release, 2011, 155(2):282-288.
|
| [22] |
Sanz V, Coley HM, Silva SR, et al. Protamine and chloroquine enhance gene delivery and expression mediated by RNA-wrapped single walled carbon nanotubes[J]. J Nanosci Nanotechnol, 2012, 12(3):1739-1747.
|